Epirus Biopharmaceuticals Inc  

(Public, NASDAQ:EPRS)   Watch this stock  
Find more results for Mallinckrodt Inc.�
5.72
-0.73 (-11.32%)
Jan 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.53 - 6.11
52 week 3.78 - 17.40
Open 6.01
Vol / Avg. 0.00/59,676.00
Mkt cap 84.31M
P/E     -
Div/yield     -
EPS -4.84
Shares 12.93M
Beta 1.52
Inst. own 57%
Mar 11, 2015
Q4 2014 Epirus Biopharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Jan 12, 2015
Epirus Biopharmaceuticals Inc at EBD Biotech Showcase
Nov 10, 2014
Q3 2014 EPIRUS Biopharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -262.15%
Operating margin - -252.60%
EBITD margin - -172.63%
Return on average assets -158.53% -113.30%
Return on average equity -197.12% -
Employees 27 -
CDP Score - -

Address

699 Boylston St Fl 11
BOSTON, MA 02116-2848
United States - Map
+1-617-6004164 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AEC EDUCATION PLC, incorporated in July, 8, 2004, is an investment holding company. The Company principal activities include investment holding and the provision of educational consultancy services. The Schools of the Company are AEC Singapore, Malvern House, and Malvern International. The courses offered by the Company are certificate, diploma and pre-university programs, university degree and postgraduate programs, preparatory courses for professional examinations, tuition services for secondary school students and English language teaching. The Company provides its services in Vietnam, China, Indonesia, Thailand, Korea, Hong Kong, Mongolia and Taiwan as well as Singapore and Malaysia. The Group currently has approximately 14,000 students enrolled on courses provided through subsidiaries and associate companies.

Officers and directors

Amit Munshi President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Thomas Shea Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
J. Kevin Buchi Director
Bio & Compensation  - Reuters
Mark H. N. Corrigan M.D. Director
Age: 56
Bio & Compensation  - Reuters
Geoffrey M. Duyk M.D., Ph.D. Director
Age: 54
Bio & Compensation  - Reuters
Daotian Fu Director
Bio & Compensation  - Reuters
Julie McHugh Director
Bio & Compensation  - Reuters